What is it about?
A subtype of melanoma carries particularly large amounts of UV-induced mutations. This seems to increase the response rates of anti PD1 therapy.
Featured Image
Read the Original
This page is a summary of: Tumor mutational burden and response to PD-1 inhibitors in a case series of patients with metastatic desmoplastic melanoma, Journal of the American Academy of Dermatology, December 2018, Elsevier,
DOI: 10.1016/j.jaad.2018.12.020.
You can read the full text:
Contributors
The following have contributed to this page
